Citius Oncology, INC

Citius Oncology announced Phase 1 clinical data for LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies, showing durable responses and manageable tolerability.

Citius Oncology reports $5.6 million in six-month net revenue for LYMPHIR and secures $36.5 million in new financing.

Citius Oncology announced a $25 million senior secured term loan facility from Avenue Capital Group and an $11.5 million warrant exercise, totaling $36.5 million to fund LYMPHIR commercialization.

Citius Oncology has been notified by Nasdaq that its common stock has fallen below the minimum $1.00 bid price requirement for continued listing.

Citius Oncology provides a positive commercial update on the U.S. launch of LYMPHIR, highlighting early adoption, broad payer coverage, and expanding clinical development.

Citius Oncology announced positive topline safety and efficacy results from a Phase 1 trial of LYMPHIR in high-risk relapsed or refractory diffuse large B-cell lymphoma patients.

Citius Oncology, Inc. reported its first revenue from LYMPHIR sales in Q1 2026, significantly narrowing its net loss, but faces ongoing going concern doubts and a need for further capital.

Citius Oncology reports increased losses and a going concern warning despite FDA approval for LYMPHIR and recent capital raise, as it prepares for commercial launch.

Citius Oncology's Q2 2025 report reveals a net loss of $14.4 million and raises concerns about its ability to continue as a going concern due to reliance on funding from Citius Pharma and the need for additional capital.

Citius Oncology's Q1 2025 report highlights ongoing efforts to commercialize LYMPHIR, with increased operating expenses and reliance on funding from Citius Pharma.

Citius Oncology, formerly TenX Keane Acquisition, reported a net income of $742,291 for the first six months of 2024, primarily driven by interest income from its trust account, while progressing towards a business combination with Citius Pharmaceuticals.

TenX Keane Acquisition reported a net income of $489,829 for the first quarter of 2024, primarily driven by investment income, while actively pursuing a business combination with Citius Oncology.

Citius Oncology launched its lead product LYMPHIR in December 2025, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and a need for significant additional funding.

Citius Oncology files an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, security ownership, related transactions, and accountant fees.

Citius Oncology's annual report highlights the FDA approval of LYMPHIR, its lead product, and outlines the company's financial status and future strategies.

TenX Keane Acquisition's 2023 annual report outlines its financial status, merger agreement with Citius Oncology, and efforts to extend its business combination deadline.

Citius Oncology's Director, Robert Joseph Smith, was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology's Director, Dennis M. McGrath, was granted 300,000 restricted stock units vesting on the third anniversary of the grant date.

Citius Oncology's Director, Joel David Mayersohn, was granted 300,000 restricted stock units vesting on the third anniversary of the grant date.

Citius Oncology, Inc. director Suren G. Dutia was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology, Inc. Director Eugene Myron Holuka was granted 300,000 restricted stock units, vesting fully on the third anniversary of the grant date.

Citius Oncology Director Carol Webb received a grant of 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, an increase in shares for its stock incentive plan, and auditor ratification.

Citius Oncology's majority stockholders approved an amendment to increase the company's authorized shares of common stock from 100 million to 400 million.

Citius Oncology is set to increase its authorized shares of common stock from 100 million to 400 million following stockholder approval via written consent.

Citius Oncology, Inc. is offering up to 5,319,149 shares of common stock and accompanying warrants to raise an estimated $13.65 million to fund the commercialization of its FDA-approved oncology drug LYMPHIR, despite significant financial challenges and a going concern warning.

Citius Oncology, Inc. has filed an S-1 registration statement to raise up to $15 million through a public offering of common stock and warrants, aiming to fund the commercialization of its recently FDA-approved oncology drug LYMPHIR, while facing substantial doubt about its ability to continue as a going concern.

Citius Pharmaceuticals, Inc. increased its beneficial ownership in Citius Oncology, Inc. to 77.9% following a registered direct offering.

Citius Pharmaceuticals, Inc.'s beneficial ownership in Citius Oncology, Inc. decreased to 79.1% following a registered direct offering by the subsidiary.

Citius Pharmaceuticals, Inc. maintains an 84.3% beneficial ownership in Citius Oncology, Inc. after Citius Oncology's recent public offering of common shares.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,299,917 shares, representing 9.99% of the outstanding common stock of Citius Oncology, Inc.

Armistice Capital, LLC and Steven Boyd report a 9.79% beneficial ownership stake in Citius Oncology, Inc. common stock.